

FORM PTO-1390 (Modified)
(REV 11-98)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES

FLA-0037

DESIGNATED/ELECTED OFFICE (DO/EO/US)

U.S. APPLICATION NO (IF KNOWN, SEE 37 CFR

CONCERNING A FILING UNDER 35 U.S.C. 371

09/508907

INTERNATIONAL APPLICATION NO.

INTERNATIONAL FILING DATE

PRIORITY DATE CLAIMED

PCT/EP98/05652**5 September 1998****25 September 1997**

TITLE OF INVENTION

ACIDIC ADDITION SALTS OF MORPHINE ALKALOIDS AND THE APPLICATION THEREOF

APPLICANT(S) FOR DO/EO/US

HOFFMANN, Rainer et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☒ has been transmitted by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ A copy of the International Search Report (PCT/ISA/210).
8. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
9. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
10. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).

Items 13 to 20 below concern document(s) or information included:

13. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☐ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ Certificate of Mailing by Express Mail
20. ☒ Other items or information:

- 1) A copy of the New Claims in Response to the Written Opinion filed 6 March 1999
- 2) Return Post Card

"Express Mail" Label No. **EL454545585US**
Date of Deposit **16 MARCH 2000**

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box PCT, Washington, D.C. 20231.

By Deborah Ehret
Typed Name: Deborah Ehret

U.S. APPLICATION NO. (IF KNOWN, SPECIFY) <div style="font-size: 1.5em; font-weight: bold; margin-top: 5px;">09/508907</div>		INTERNATIONAL APPLICATION NO <div style="font-weight: bold; margin-top: 5px;">PCT/EP98/05652</div>		ATTORNEY'S DOCKET NUMBER <div style="font-weight: bold; margin-top: 5px;">FLA-0037</div>	
--	--	---	--	---	--

21. The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) : <div style="margin-top: 5px;"> <input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$970.00 <input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$840.00 <input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$690.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00 <input type="checkbox"/> International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00 </div> <div style="text-align: right; margin-top: 5px;"> ENTER APPROPRIATE BASIC FEE AMOUNT = </div>				CALCULATIONS PTO USE ONLY	
				\$840.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).				\$0.00	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		
Total claims	16 - 20 =	0	x \$18.00	\$0.00	
Independent claims	2 - 3 =	0	x \$78.00	\$0.00	
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>				\$0.00	
TOTAL OF ABOVE CALCULATIONS =				\$840.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). <input type="checkbox"/>				\$0.00	
SUBTOTAL =				\$840.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).				\$0.00	
TOTAL NATIONAL FEE =				\$840.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>				\$0.00	
TOTAL FEES ENCLOSED =				\$840.00	
				Amount to be: refunded	\$
				charged	\$

☒ A check in the amount of **\$840.00** to cover the above fees is enclosed.

☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees.
 A duplicate copy of this sheet is enclosed.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **12-1086** A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Jane Massey Licata, Reg. No. 32,257

Law Offices of Jane Massey Licata
66 E. Main Street
Marlton, New Jersey 08053

Telephone: (856) 810-1515

Facsimile : (856) 810-1454

Jane Massey Licata
SIGNATURE

LICATA, Jane Massey

NAME

32,257

REGISTRATION NUMBER


16 March 2000

DATE

5/PRTS

ACIDIC ADDITION SALTS OF MORPHINE ALKALOIDS AND THE USE
THEREOF

The invention relates to substances consisting essentially of the acid addition salt of a morphine alkaloid and an organic acid, said morphine alkaloid having the following formula I:



where R^1 is selected from the group consisting of H, C_1 - to C_6 -alkyl residues, preferably methyl, ethyl, propyl, isopropyl, $C(O)CH_3$; R^2 selected from the group consisting of H, OH, $OC(O)CH_3$, =O, =CH₂; R^3 selected from the group consisting of -CH₃, cyclopropyl, cyclobutyl and allyl; and where the bond at C7/C8 may be saturated or a nitroxyl group may be present at N₁₇.

Morphine alkaloids, especially morphine, belong to the group of strong analgesics; their therapeutic use lies, inter alia, in the field of treatment of intense and extremely intense conditions of pain occurring, for example, in many cases of carcinosis in the final stage, or following accidents.

The heretofore existing possibilities of administration (oral, parenteral) employing these substances are dissatisfactory. There is a danger of acid-catalyzed chemical changes taking place in the stomach. In addition, these administration forms result in high variations in the plasma

level, which are observed, in particular, in the case of parenteral application (injection). Due to the plasma concentrations obtained either falling short of or exceeding the therapeutically desired plasma concentrations, habit-forming effects occur.

From US-A 4,626,539 pharmaceutical compositions are known containing an opioid substance, e.g. morphine, or pharmaceutically acceptable salts thereof. Pharmaceutically acceptable salts described in this patent document are acetates, napsylates, tosylates, succinates, hydrochlorides, palmitates, stearates, oleates, parmoates, laurates, valerates, hydrobromides, sulfates, methane sulfonates, tartrates, citrates and maleates.

From US-A 5,374,645 there are known compositions for the transdermal administration of ionic pharmaceutically active agents, whereby morphine or its pharmaceutically acceptable salts is among the substances mentioned in this context. Salts mentioned in addition to the above morphine salts are oxalates, pyruvates, cinnamates, acetates, trifluoroacetates as well as salicylates and some other substances.

US-A 4,879,297 describes pharmaceutical compositions containing opioids or the pharmaceutically acceptable salts thereof, describing as salts in particular those of certain fatty acids such as palmitates, stearates, oleates and parmoates.


Furthermore, in US-A 4,908,389 active substance-containing compositions for topical application are described containing the active substances in the form of acid addition salts such as hydrochlorides, hydrobromides, orthophosphates, benzoates, maleates, tartrates, succinates, citrates, salicylates, sulfates or acetate.

The dermal or topical application of one of the above-stipulated acid-addition salts of morphine alkaloids has the disadvantage of very poor skin permeability of the salts mentioned. In the case of the known compositions it is attempted to compensate this drawback by adding so-called enhancers to the administration forms.

Even though this method sometimes leads to the desired success, it would be preferable, from a pharmaceutical or therapeutic point of view as well under the aspect of legal approval, if morphine alkaloid salts were available that per se had a higher permeability through the skin, so that no additional substance would be required or only a small amount thereof. The reason for this being, in particular, that the use of the above-mentioned enhancers, even if applied on the skin, leads to disadvantageous effects such as skin irritations or undesired pharmacodynamic side effects due to excessive toxicity.

Thus, it is the object of the present invention to provide acid addition salts of morphine alkaloids of the above-mentioned formula I which have improved properties as compared to the known salts. In particular, their permeability through the skin is to be increased.

This object is solved by providing a substance consisting substantially of the acid addition salt of a morphine alkaloid and an organic acid, said morphine alkaloid having the following formula I:



(I)

where R^1 is selected from the group consisting of H, C_1 - to C_6 -alkyl residues, preferably methyl, ethyl-, propyl, i-propyl, $C(O)CH_3$; R^2 selected from the group consisting of the monad residues H, OH, $OC(O)CH_3$, whereby in this case the fourth valence of the (6)-C atom is occupied by H, or the dyad residues $=O$, $=CH_2$; R^3 is selected from the group consisting of $-CH_3$, cyclopropyl, cyclobutyl and allyl; and where

- the bond at C7/C8 may be saturated, or a nitroxyl group may be present at N_{17}

and the organic acid is selected from:

- monoesters of C_3 - to C_{16} -dicarboxylic acids with monohydric C_1 - to C_4 -alcohols, especially methanol,
- C_2 - to C_{16} -sulfonic acids,
- substituted benzoic acids, selected from the group of halogen-, hydroxy-, alkyl-, hydroxyalkyl-, alkoxyalkyl- and/or alkoxy-substituted benzoic acid, as well as of the aminosubstituted benzoic acids, which may optionally be alkylated at the N atom.
- substituted or non-substituted 5-ring or 6-ring heterocycles comprising at least one N or S atom and having a carboxyl group function, especially a carboxy, carboxymethyl, carboxyethyl or the - optionally branched - carboxypropyl or carboxybutyl groups as substituents,

- saturated or unsaturated, optionally substituted, oxo-carboxylic acids having 5 to 10 C atoms,
- phenyl-substituted or phenoxy-substituted saturated C₂- to C₄-carboxylic acids.
- aliphatic, aromatic or heterocyclic C₂- to C₁₂-amino acids, wherein an amino group is substituted with an - optionally substituted - C₂- to C₆-alkanoyl group or an - optionally substituted - benzoyl group.

Preferred embodiments are the subject-matter of the sub-claims.

The substance according to the invention substantially consists of an acid-addition salt of a morphine alkaloid of the aforementioned formula I and a further organic acid. The term "substantially consisting of" signifies that impurities are contained only to an extent which is common. The substance respectively the composition according to the present invention can be prepared and purified employing methods commonly used in preparative organic chemistry, so that the purified substance can also be provided in p.A. or p.p.A. purity. The acid is, in particular, pharmaceutically acceptable. It, too, can be produced by means common methods if it is not yet available on the market.

In the case of the morphine alkaloid of the above-mentioned formula I, R¹ is selected from the group consisting of H, C₁- to C₆-alkyl residues and C(O)CH₃. The C₁- to C₆-alkyl residues preferably are methyl, ethyl, propyl or i-propyl residues. The R² residue is a monad residue from the group of H, OH, OC(O)CH₃, the fourth valence at the (6)-C atom in this case being occupied by H. As an alternative, R² may

also be one of the dyad residues $=O$ or $=CH_2$. R^3 is selected from the group consisting of $-CH_3$, cyclopropyl, cyclobutyl and allyl. Furthermore, the double bond between C7/C8 may be saturated. Apart therefrom, a nitroxyl group may be present at N 17. In the above-numerated organic residues, C(O) refers to a carbonyl function.

The acid component of the acid-addition salt according to the present invention is selected from monoesters of C_3 - to C_{16} -dicarboxylic acids with monohydric C_1 - to C_4 -alcohols, from C_2 - to C_{16} -sulfonic acids, from substituted benzoic acids selected from the group of halogen, hydroxy, alkyl, hydroxyalkyl, alkoxyalkyl-substituted and/or amino-substituted benzoic acids, the latter optionally being alkylated at the N atom, from substituted or non-substituted, saturated or unsaturated 5-ring or 6-ring heterocycles having at least one N atom or S atom and having one of the already mentioned carboxyl group functions as substituents, a carboxyl group being especially preferred as substituent, from saturated or unsaturated - optionally substituted - oxocarboxylic acids having 5 to 10 C atoms, or from phenyl-substituted or phenoxy-substituted saturated C_2 - to C_4 -carboxylic acids, especially acetic acid. Naturally, C_3 - to C_{16} -dicarboxylic acids here refer to carboxylic acids having a total carbon number of 5 to 18 C atoms.

The alkyl, hydroxyalkyl or alkoxyalkyl-substituted benzoic acids are, above all, those, wherein the alkyl residue or even alkoxy residue at the benzoic acid nucleus has 1 to 12 C atoms. These alkyl or alkoxy residues may also be branched. Examples therefor are i-propyl, 2-methylpropyl, t-butyl residues, 2-methylbutyl residues or the corresponding alkoxy residues. The benzoic acid nuclei may also be polysubstituted; as a matter of course, they may also be

substituted with various of the alkyl or alkoxy residues mentioned.

What has been said above regarding the alkyl or alkoxy residues at the benzoic acid nucleus of the alkyl-substituted or alkoxy-substituted benzoic acids also applies - with reference to the alkyl or alkoxy part of the alkoxyalkyl residue in respect of the number of carbon atoms or the branching - in the case of benzoic acids substituted with alkoxyalkyl residues.

Also possible and preferred as alkoxy substituents in preferred alkoxyalkyl-substituted benzoic acids are C₁- to C₆-alkoxy groups, especially methyloxy, ethyloxy or propyloxy groups. These alkoxy groups are etherified with C₁- to C₄-hydroxyalkyl, especially with hydroxymethyl, hydroxyethyl or hydroxypropyl groups.

The aminosubstituted benzoic acids may optionally also be alkylated at the amino group - in particular with C₁- to C₄-alkyl residues.

Preferred substituted benzoic acids are halogen, C₁- to C₆-alkyl, hydroxy-(C₁- to C₆)-alkyl, amino-substituted or hydroxy-substituted benzoic acids. The amino-substituted benzoic acids may in turn be substituted at the amino group - as explained above. In the case of aminobenzoic acid, the amino group is, in preferred embodiments, either non-substituted or monosubstituted or disubstituted with C₁- to C₄-alkyl groups. Especially preferred alkyl-substituted benzoic acids are monosubstituted or polysubstituted C₁- to-C₄-alkyl-substituted benzoic acids, preferably C₁- to C₄-trialkyl-substituted benzoic acids, whereby the alkyl residues may also vary.

Examples for preferred hydroxyalkyl-substituted benzoic acids are hydroxymethylated, hydroxyethylated, hydroxypropylated or hydroxybutylated benzoic acids.

Among the above-stipulated hydroxy-substituted benzoic acids, the p- or m-hydroxy-substituted benzoic acids are especially preferred.

Most preferred among the substituted benzoic acids for the acid component of the acid-addition salts of morphine alkaloids of the above-mentioned Formula I according to the present invention are p-hydroxybenzoic acid, p-aminobenzoic acid or trimethylbenzoic acid, especially 2,4,6-trimethylbenzoic acid.

The substituted or non-substituted 5-ring or 6-ring heterocycles used according to the invention as acid components for morphine alkaloid acid addition salts are cyclic 5-ring or 6-ring systems comprising at least one nitrogen or S atom, such as, in particular, pyridine, piperidine, pyrimidine or analogous pyrrole or thiophene ring systems. These ring systems additionally carry a carboxyl group at one ring atom. Naturally, the heterocyclic ring system may also be saturated, as is already evident from the piperidine ring system.

The 6-ring heterocycles are, preferably, substituted or non-substituted pyridinecarboxylic acid, especially nicotinic acid. Among the preferred 5-ring systems having at least one S-atom there is lipoic acid.

As mentioned above, the morphine alkaloid acid addition salts may, with respect to the acid component, also consist of C₂- to C₁₆-sulfonic acids. Of these sulfonic acids,

C₄- to C₈-sulfonic acids, especially hexanesulfonic acid, are particularly preferred.

The monoesters of C₃- to C₁₆-dicarboxylic acids with monohydric C₁- to C₄-alcohols, especially methanol, used in the case of the morphine alkaloid acid addition salts according to the present invention are preferably monoesters of C₅- to C₁₀-dicarboxylic acids with the above-mentioned alcohols.

In this context, substances especially preferred as acids are suberic acid, azelaic acid or sebacic acid. Among the aforementioned monoesters of dicarboxylic acids, monomethylsebacate is most preferred.

If, in accordance with the invention, a saturated or unsaturated, e.g. olefinically unsaturated, and optionally substituted, oxocarboxylic acid having 5 to 10 C atoms is used as acid component of the morphine-alkaloid acid addition salt, preferably this is - optionally olefinically unsaturated - 2-, 4-, 5- or 9-oxocarboxylic acid. Among these oxocarboxylic acids, 5-oxopyrrolidine-2-carboxylic acids (pyroglutamic acid), levulinic acid or oxo-dec-2-ene acid are the most advantageous.

If as an acid component for the morphine alkaloid acid addition salts according to the invention a phenyl-substituted or phenoxy-substituted C₂- to C₄-carboxylic acid is used, this is preferably a phenyl-substituted or phenoxy-substituted acetic, propionic or butyric acid.

The aliphatic, aromatic or heterocyclic C₂- to C₁₂-amino acids used according to the invention are preferably monoaminomonocarboxylic acids, wherein the amino group is sub-

stituted with a C₂- to C₆-alkanoyl group, which may be mono- or polysubstituted with hydroxy, C₁- to C₄-alkoxy- or C₁- to C₄-hydroxyalkyl, or wherein the amino group is substituted with the benzoyl residue, which may be mono- or polysubstituted with C₁- to C₄-alkyl, C₁- to C₄-alkoxy, C₁- to C₄-hydroxyalkyl, halogen, amino or hydroxy.

The aromatic amino acids may be, for example, phenyl amino acids, preferably phenylalanine and tyrosine; the heterocyclic amino acids are preferably proline, hydroxyproline and tryptophan. Especially preferred are, however, aliphatic C₂- to C₆-monoaminomonocarboxylic acids, wherein the amino group is substituted, as indicated above; it is, however, especially preferred if the amino group is substituted with the acetyl group or benzoyl group.

The alkaloid component of the morphine alkaloid acid addition salts according to the present invention are preferably the morphine alkaloids morphine, codeine, heroin, ethylmorphine, levorphanol or hydromorphone.

Generally, of the above-mentioned acid addition salts according to the invention those are especially preferred whose molecular mass (MW) is below 800, preferably below 600, and most advantageously between 400 and 600.

According to the invention there are also provided mixtures of the above-mentioned substances, whereby either the same morphine alkaloid is reacted with various acid components, or the same acid component is combined with various morphine alkaloids. Of course, such a composition may also contain a combination of the two aforementioned variants. In a preferred embodiment, the composition is a solution or suspension of the acid addition salts according to the invention in glycerol, ethylene glycol, oleic acid, dimeth-

ylisosorbide and/or dimethylsulfoxide, whereby such solution or suspension may also contain further components, such as penetration enhancers.

Especially preferred penetration enhancers are polyoxethylene sorbitane fatty acids, such as Tween 20, or polyoxyethylene alcohols, such as, for example, polymerisation products of up to 10 molecules ethylene oxide, each with one molecule octanol, decanol or dodecanol, or mixtures of these polymerization products.

The morphine alkaloid acid addition salts are prepared by way of known process steps. Such a production method comprises the steps of providing a solution of the basic alkaloid, reacting, in a further step, said solution with equimolar amounts of a solution of the organic acid or - if the acid is liquid - reacting the solution directly with said acid, and isolating the addition salt thus obtained by means of common process steps.

In accordance with the invention, the above-described substances or compositions are employed in preparations for transdermal or transmucosal administration. They are used above all for pain control or in withdrawal therapies of drug addicts. Such preparations for transdermal or transmucosal administration are, for example, lotions, ointments, cremes, gels or sprays, transmucosal therapeutic systems, transdermal therapeutic systems (TTS) or iontophoretic devices. Such transdermal or transmucosal therapeutic systems are in principle known to those skilled in the art. They are described, for example, in "Therapeutische Systeme" [Klaus Heilmann, 4th ed., Ferdinand Enke Verlag, Stuttgart (1984)].

If the preparation for transdermal administration is a TTS, this comprises a - preferably active substance-impermeable

- backing layer and a reservoir layer. The reservoir layer preferably contains 40 - 80%-wt polymer material. This polymer material is preferably selected from the group of polyacrylates, silicones or polystyrenes. Furthermore, the reservoir layer preferably contains 0.1 - 30%-wt plasticizer as well as the morphine alkaloid acid addition salts according to the invention in an amount of from 0.1 to 30%-wt.

The backing layer may consist of flexible or non-flexible material. Examples of materials used for its manufacture are polymer films or metal foils, such as aluminium foil, which are used on their own or coated with a polymer substrate. Textile fabrics may also be used, provided that the components of the reservoir can not penetrate the fabrics due to their physical properties.

In a preferred administration form the backing layer is a composite material of an aluminized layer.

The reservoir layer contains - as mentioned above - a polymer matrix and the active substance, the polymer matrix ensuring the coherence of the system. It comprises a base polymer and optionally further common additives. The selection of the base polymer is dependent on the chemical and physical properties of the salts according to the present invention. Examples of polymers are rubber, rubber-like synthetic homopolymers, copolymers or blockpolymers, polyacrylic acid esters and their copolymers, polyurethanes and silicones. In principle, any polymers are suitable which can also be used in the production of pressure-sensitive adhesives and which are physiologically acceptable. Especially preferred are those based on blockpolymers of styrene and 1,3-dienes, polyisobutylenes, silicones and acrylate-based and/or methacrylate-based polymers.

What kind of common additives are employed depends on the polymer used: According to their function, they can be divided, for example, in tackifying agents, stabilizers, carriers and fillers. Physiologically acceptable substances suitable for this purpose are known to the man skilled in the art.

The reservoir layer has such self-adhesiveness as to ensure permanent contact to the skin. It may also have a multi-layered structure.

The selection of the plasticizer - which may simultaneously serve as a solvent - is dependent on the active substance in the polymer.

A removable protective layer, which is in contact with the reservoir layer and is removed prior to application, may also be made up of the same materials as are used for producing the backing layer, with the prerequisite that these materials have been rendered removable, such as, for example, by means of silicone treatment. Other removable layers are, for example, polytetrafluoroethylene, treated paper, cellophane, polyvinylchloride and the like.

A TTS will initially be present in an initial stage as a laminate. If the laminate is divided into formats suitable for therapy (patches) prior to application of the protective layer, the protective layer pieces to be applied subsequently may have a projecting end, with the aid of which said pieces can be removed more easily.

In the case of transmucosal administration of the salts according to the present invention, it is preferred to use a mucoadhesive additive for more rapid absorption through the mucous membrane.

Such additives are, for example, polyacrylic acid carboxymethylcellulose and other derivated polysaccharides, especially acetyl starch or hydroxyethyl starch or combinations thereof.

The transdermal system may be prepared by homogeneously mixing the active substance together with the other components of the pressure-sensitive reservoir layers, optionally in solution, and applying same onto the - optionally active substance-impermeable - backing layer, whereupon the solvent(s) is/are removed. Subsequently, the adhesive layer is provided with a corresponding protective layer.

The invention will be illustrated in more detail by means of the following Figures and Examples:

The Figures show:

- Fig. 1: the ^1H -NMR spectrum of the morphine base in CDCl_3 at 400 MHz.
- Fig. 2: the ^1H -NMR spectrum of the morphine trimethylbenzoate in CDCl_3 at 400 MHz.
- Fig. 3: The table shows the association of the individual proton signals in the ^1H -NMR spectrum of the morphine base as well as of the morphine trimethylbenzoate, according to their chemical shift (characterization as morphine salt).

By means of NMR spectroscopy it is possible to monitor the protonation of the alkaloid function in the morphine molecule. The salt formation has an impact on the electron distribution in the piperidine portion. A lower field shift of the proton resonance signals in the region of the base function shows that the protons there are de-

shielded through salt formation. On the one hand, this is due to the acidic trimethylbenzoic acid proton being bonded by the free electron pair at the basic nitrogen, and, on the other hand, to the influence of the trimethylbenzoic acid residue.

Fig. 4: The Table shows the results of measurements of the penetration behaviour of various morphine salts according to the present invention, and of comparison substances. The preparations are self-prepared; identification was performed by means of IR-ATR and H-NMR spectrums.

Fig. 5: This diagram shows the permeation behaviour of morphine monomethyl sebacate in comparison to morphine base, in each case from one TTS, as described in Utilization Example 1. The penetration rate of the salt lies above that of the base by a factor of ca. 1.8. The incorporated amount of salt corresponds to 10%-wt morphine base, thus being equimolar to the reference TTS of the morphine base.

PRODUCTION EXAMPLE 1:

1 g (3.5 mMol) water-free morphine base were dissolved, while heating, in 100 ml methanol. Once the base had been completely dissolved in methanol, a solution of 756 mg (3.5 mMol) monomethylsebacic acid in 20 ml methanol was added. The combined solutions were narrowed down in the rotary evaporizer. After ca. 48 h at 5 °C the morphine monomethyl sebacate had crystallized. Solvent residues were removed using a vacuum pump. The crystals had a melting point of 146 °C.

PRODUCTION EXAMPLE 2:

Production Example 1 was repeated, except that instead of the monomethylsebacic acid an equimolar amount of p-hydroxybenzoic acid was used.

PRODUCTION EXAMPLE 3:

Production Example 1 was repeated, with the exception that instead of monomethylsebacic acid an equimolar amount of oxoproline was used.

PRODUCTION EXAMPLE 4:

Production Example 1 was repeated, except that instead of monomethylsebacic acid an equimolar amount of hexanesulfonic acid was used.

PRODUCTION EXAMPLE 5:

Production Example 1 was repeated, except that instead of monomethylsebacic acid an equimolar amount of nicotinic acid was used.

PRODUCTION EXAMPLE 6:

Production Example 1 was repeated, except that instead of monomethylsebacic acid an equimolar amount of p-amino-benzoic acid was used.

PRODUCTION EXAMPLE 7:

Production Example 1 was repeated, except that instead of monomethylsebacic acid an equimolar amount of 2,4,6-trimethylbenzoic acid was used.

PRODUCTION EXAMPLE 8:

Production Example 1 was repeated, except that instead of monomethylsebacic acid an equimolar amount of lipoic acid was used.

PRODUCTION EXAMPLE 9:

Production Example 1 was repeated, except that instead of monomethylsebacic acid an equimolar amount of acetylglycin was used.

PRODUCTION EXAMPLE 10:

Production Example 1 was repeated, except that instead of the monomethylsebacic acid an equimolar amount of hippuric acid was used.

COMPARISON EXAMPLE 1:

Production Example 1 was repeated, with the exception that instead of the salt of monomethylsebacic acid and morphine, only an equivalent amount of morphine base was used.

COMPARISON EXAMPLE 2:

Production Example 1 was repeated, except that instead of monomethylsebacic acid an equimolar amount of propionic acid was used.

COMPARISON EXAMPLE 3:

Production Example 1 was repeated, with the exception that instead of monomethylsebacic acid an equimolar amount of formic acid was used.

UTILIZATION EXAMPLE 1:

1.654 g morphine monomethylsebacate (corresponding to 10%-wt morphine base) were incorporated in 2.346 g oleic acid. Subsequently, this was stirred until complete dissolution of the solid substance (ca. 15 minutes, visual control). The solution was then, again under stirring, stirred in portions into 12.3 g of a self-crosslinking acrylate polymer of 2-ethylhexyl acrylate, vinyl acetate and acrylic acid (48,8%-wt., in a solvent mixture ethyl acetate : heptane).

tane : ethanol : 2-propanol 39 : 13 : 22 : 26). This was then stirred for ca. 2 hours, at room temperature. The evaporation loss was compensated with ethyl acetate. 10 g 48.8%-wt. active substance-containing adhesive solution were yielded and coated onto an aluminized and siliconized polyethylene film. After removal of the solvents by drying for 30 minutes at up to 50 °C, the adhesive film was covered with a 15-µm-thick polyester film. Using appropriate cutting tools, the intended application surfaces were punched out and the margins removed through separation by lattice.

UTILIZATION EXAMPLE 2:


30 mg of morphine-p-hydroxybenzoate were suspended in 1.47 g olive oil. The 2%-wt trituration thus obtained was applied, using an application device, to excised nude guinea pig skin which, in turn, had been clamped into a FRANZ' diffusion cell tempered at 37 °C. As acceptor solution, 0.9% sodium chloride solution was used, which, under continued stirring, was likewise maintained at 37 °C and completely replaced by a new acceptor solution. The results of the amounts penetrated from the donor portion, determined through HPLC, are set out in Fig. 4.

UTILIZATION EXAMPLES 3 to 14:

Utilization Example 2 was repeated with the modification that instead of morphine-p-hydroxybenzoate, in the trituration the morphine salts of the Production Examples 3 to 10, or the substances of the Comparison Examples 1 to 3 were used. The results are likewise set out in Fig. 4.

NEW CLAIMS

1. Transdermal or transmucosal composition for administering morphine alkaloids of the following Formula I:



where R^1 is selected from the group consisting of H, C_1 - to C_6 -alkyl residues, preferably methyl, ethyl-, propyl, i-propyl, $C(O)CH_3$; R^2 is selected from the group consisting of the monad residues H, OH, $OC(O)CH_3$, whereby in this case the fourth valence of the (6)-C atom is occupied by H, or the dyad residues $=O$, $=CH_2$; R^3 is selected from the group consisting of $-CH_3$, cyclopropyl, cyclobutyl and allyl; and where

- the bond at C7/C8 may be saturated, or a nitroxyl group may be present at N_{17} ,

characterized in that it contains the morphine alkaloid as an acid addition salt of an organic acid which is selected from

- monoesters of C_3 - to C_{16} -dicarboxylic acids with monohydric C_1 - to C_4 -alcohols, especially methanol,
- C_2 - to C_{16} -sulfonic acids,
- substituted benzoic acids, selected from the group of halogen, hydroxy, alkyl, hydroxyalkyl, alkoxyalkyl

and/or alkoxy-substituted benzoic acids, as well as of the aminosubstituted benzoic acids, which may optionally be alkylated at the N atom,

- substituted or non-substituted 5-ring or 6-ring heterocycles comprising at least one N or S atom and having a carboxyl group function, especially a carboxy, carboxymethyl, carboxyethyl or the - optionally branched - carboxypropyl or carboxybutyl groups as substituents,
- saturated or unsaturated, optionally substituted, oxocarboxylic acids having 5 to 10 C atoms,
- phenyl-substituted or phenoxy-substituted saturated C₂- to C₄-carboxylic acids,
- aliphatic, aromatic or heterocyclic C₂- to C₁₂-amino acids, wherein one amino group is substituted with an - optionally substituted - C₂- to C₆-alkanoyl group or an - optionally substituted - benzoyl group.

2. Composition according to Claim 1, characterized in that the organic acid is selected from aliphatic monoamino-monocarboxylic acids, wherein the amino group is substituted with a C₂- to C₆-alkanoyl group, which may be mono- or polysubstituted with hydroxy, C₁- to C₄-alkoxy- or C₁- to C₄-hydroxyalkyl, or wherein the amino group is substituted with the benzoyl residue, which may be mono- or polysubstituted with C₁- to C₄-alkyl, C₁- to C₄-alkoxy, C₁- to C₄-hydroxyalkyl, halogen, amino or hydroxy.

3. Composition according to Claim 2, characterized in that the organic acid is selected from aliphatic C₂- to C₆-

monoaminomonocarboxylic acids, wherein the amino group is substituted with the acetyl group or the benzoyl group.

4. Composition according to Claim 1, characterized in that the organic acid is selected from:

- hydroxy-(C₁- to C₄)-alkyl, C₁- to C₆-alkoxy-(C₁- to C₄)-alkyl-substituted or p- or m-hydroxy-substituted benzoic acids,
- monoesters of C₅- to C₁₀-dicarboxylic acids, especially suberic acid, azelaic acid and sebacic acid,
- C₄- to C₈-sulfonic acids, especially hexanesulfonic acid.

5. Composition according to Claim 1, characterized in that the acid is selected from C₁- to C₄-alkyl-substituted benzoic acids, preferably C₁- to C₄-trialkyl-substituted benzoic acids.

6. Composition according to Claim 1, characterized in that the organic acid is hexanesulfonic acid, aminobenzoic acid or trimethylbenzoic acid.

7. Composition according to Claim 1, characterized in that the 5-ring or 6-ring heterocycle is a pyridine-carboxylic acid, preferably nicotinic acid or lipoic acid.

8. Composition according to Claim 1, characterized in that the oxocarboxylic acid is a 2-, 4-, 5- or 9-oxocarboxylic acid which is optionally unsaturated.


9. Composition according to Claim 8, characterized in that the oxocarboxylic acid is 5-oxopyrrolidine-2-carboxylic acid, levulic acid or oxodec-2-ene acid.

10. Composition according to Claim 3, characterized in that the organic acid is acetylglycin or hippuric acid.

11. Composition according to any one of the preceding Claims, characterized in that the morphine alkaloid is morphine, codeine, heroin, ethylmorphine, levorphanol or hydromorphone.

12. Composition according to Claim 1, characterized in that it comprises a solution or suspension of the acid addition salt in glycerin, ethylene glykol, dimethyl isosorbide, oleic acid and/or dimethyl sulfoxide.

13. Acid addition salts of morphine alkaloid and organic acid, said morphine alkaloid having the following Formula I:



(I)

where R^1 is selected from the group consisting of H, C_1 - to C_6 -alkyl residues, preferably methyl, ethyl-, propyl, i-propyl, $C(O)CH_3$; R^2 is selected from the group consisting of the monad residues H, OH, $OC(O)CH_3$, whereby in this case the fourth valence of the (6)-C atom is occupied by H, or the dyad residues $=O$, $=CH_2$; R^3 is selected from the group consisting of $-CH_3$, cyclopropyl, cyclobutyl and allyl; and where

- the bond at C7/C8 may be saturated, or a nitroxyl group may be present at N_{17} ,

characterized in that the organic acid is selected from

- monoesters of C₃- to C₁₆-dicarboxylic acids with monohydric C₁- to C₄-alcohols, especially methanol,
- C₂- to C₆- and C₈- to C₁₆-sulfonic acids,
- the group of halogen, p- and m-hydroxy, alkyl, hydroxyalkyl, alkoxyalkyl and/or alkoxy-substituted benzoic acids, as well as of the aminosubstituted benzoic acids, which may optionally be alkylated at the N atom,
- substituted or non-substituted 5-ring or 6-ring heterocycles comprising at least one N or S atom and having a carboxyl group function, especially a carboxy, carboxymethyl, carboxyethyl or the - optionally branched - carboxypropyl or carboxybutyl groups as substituents,
- saturated or unsaturated, optionally substituted, oxocarboxylic acids having 5 to 10 C atoms,
- phenoxy-substituted saturated C₂- to C₄-carboxylic acids,
- aliphatic, aromatic or heterocyclic C₂- to C₁₂-amino acids, wherein one amino group is substituted with an - optionally substituted - C₂- to C₆-alkanoyl group or an - optionally substituted - benzoyl group.

14. Method for the production of acid addition salts according to Claim 13, comprising the steps of providing a solution of the morphine alkaloid, reacting, in a further

step, said solution with equimolar amounts of a solution of the organic acid and isolating the resultant addition salt.

15. Use of a composition according to Claim 1 for formulating preparations for pain control or for withdrawal therapy of drug addicts.

16. Composition according to Claim 1, characterized in that said preparation is a lotion, ointment, creme, gel or spray, an iontophoretic device, a transmucosal therapeutic system or a transdermal therapeutic system (TTS), comprising a backing layer, which optionally is active substance-impermeable, and a reservoir layer.

ABSTRACT

A substance consisting of an acid addition salt of a morphine alkaloid and an organic acid is provided.

The organic acid is selected from:

- monoesters of C_3 - to C_{16} -dicarboxylic acids with monohydric C_1 - to C_4 -alcohols,
- C_2 - to C_{16} -sulfonic acids,
- substituted benzoic acids, selected from the group of halogen, hydroxy, alkyl, hydroxyalkyl, alkoxyalkyl and/or alkoxy-substituted benzoic acid, as well as of the aminosubstituted benzoic acids, which may optionally be alkylated at the N atom,
- substituted or non-substituted 5-ring or 6-ring heterocycles comprising at least one N or S atom and having a carboxyl group function,
- saturated or unsaturated, optionally substituted, oxocarboxylic acids having 5 to 10 C atoms,
- phenyl-substituted or phenoxy-substituted saturated C_2 - to C_4 -carboxylic acids.
- aliphatic, aromatic or heterocyclic C_2 - to C_{12} -amino acids, wherein one amino group is substituted with an - optionally substituted - C_2 - to C_6 -alkanoyl group or an - optionally substituted - benzoyl group.

1/5




FIG. 1




FIG. 2

3/5

Chemical shift of the proton signals in the ^1H spectrum

of the morphine base and the morphine-(2,4,6)-trimethylbenzoate

Proton at the carbon No.:	Signal (Shift in ppm)	
	Morphine base	Morphinetrimethylbenzoate
15 (equatorial)	1,85	1,88
15 (axial)	2,06	2,33
10 (cis position to proton at C 9)	2,24	2,61
16 (axial)	2,41	2,70
methyl group protons at C 17	2,43	2,71
16 (equatorial)	2,59	3,11
14	2,66	3,05
10 (trans position to proton at C 9)	3,02	3,02
9	3,35	3,81
6	4,18	4,18
5	4,88	4,77
8	5,28	5,17
7	5,67	5,63
1	6,50	6,43
2	6,62	6,55
Protons of the methyl group in 4-position of the 2,4,6-trimethylbenzoic acid		2,22
Protons of the methyl groups in 2,6-position of the 2,4,6-trimethylbenzoic acid		2,28
Protons in 3,5-position at the aromatic ring of the 2,4,6-trimethylbenzoic acid		6,77

Signal at 7,25 ppm – solvent signal of the CDCl_3

Signals of protons in the neighborhood of the amine function are subjected to the strongest lower field shift, due to protonation of the nitrogen, e.g.:

Proton at C 15 (axial)	+ 0,27 ppm
Proton at C 10 (cis position to proton at C 9):	+ 0,37 ppm
Proton at C 16 (axial):	+ 0,29 ppm
Protons at the methyl group with C 17:	+ 0,29 ppm
Proton at C 16 (equatorial):	+ 0,52 ppm
Proton at C 9:	+ 0,46 ppm

Figur 3

Comparison skin permeation of various morphine salts

Type of skin: nude guinea pig (back); # 20/05-0455/00-95

Acceptor: 0.9% NaCl solution + 0.1% NaN₃

Release temperature: 37 °C

Release vehicle: olive oil

Load donor: 2 Ma%; relative to Mph salt I


Load Mph salt/cm² skin: 787.4 µgUnit of values: µg/cm² (mean values of n=3)

* Flux: sum 48 h (accumulated) – sum 24 h (accumulated) / 24

Unit of values flux: µg/cm²xh

		differential permeation values					
Mph salt		7.5 h	24 h	30 h	48 h	total	flux*
Example 1	monomethyl sebacate	3,31	12,3	7,47	24,6	47,7	1,34
Example 2	p-hydroxybenzoate	24,2	172	82	196	474	11,6
Example 3	oxo-prolinate	9,82	71,2	47,4	172	301	9,16
Example 4	hexane sulfonate	2,7	18,7	14,4	63,6	99,4	3,25
Example 5	nicotinate	22,2	99,9	55,4	167	345	9,29
Example 6	p-aminobenzoate	8,56	23,6	10,5	45,6	88,3	2,34
Example 7	trimethylbenzoate	3,7	36,3	24	102	166	5,25
Example 8	liponate	1,23	12,0	8,52	19,9	41,6	1,18
Example 9	acetyl glycinate	38,1	180,0	62,4	110	390	7,17
Example 10	hippurate	22,9	83,4	41,3	109	256	6,25
Comparison Expl. 1	[base]	3,54	3,2	2,48	8,3	17,5	0,45
Comparison Expl. 2	propionate	1,55	4,74	2,66	8,54	17,5	0,47
Comparison Expl. 3	formiate	0,342	6,46	2,54	8,6	17,9	0,46

Figur 4



Figur 5

Morphine Salts
1997/014

Attorney Docket No.: **FLA-0037**

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and

I verily believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **Acidic Addition Salts of Morphine Alkaloids and the Application Thereof** the specification of which:

() is attached hereto.

(XX) was filed on 5 September 1998 as Application Serial No. PCT/EP98/05652 and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to the patentability of this application in accordance with 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of any application on which priority is claimed:

Country	Number	Date Filed	Priority Claimed			
German	197 42 296.9	25 Sept. 1997	Yes	X	No	
			Yes		No	
			Yes		No	

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to be material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Filing Date	Status (pending, patented)

I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: **Jane Massey Licata**, Registration No. **32,257**, **Kathleen A. Tyrrell**, Registration No. **38,350**, and **Laura M. Plunkett**, Registration No. **45,015** of the firm of **Law Offices of Jane Massey Licata**, 66 East Main Street, Marlton, New Jersey 08053, and

Address all telephone calls and correspondence to:

Jane Massey Licata, Esq.

Law Offices of Jane Massey Licata
66 East Main Street
Marlton, New Jersey 08053

Telephone No.: (856) 810-1515


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the

United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1	Full Name: Rainer Hoffmann	Inventor's Signature: <i>Rainer Hoffmann</i>	Date: 10.05.2000
	Residence: Burghofstrasse 123 D-56566 Neuwied, Germany <i>DEX</i>	Citizenship: German	
	Post Office Address: Same as above.		
2	Full Name: Bodo Asmussen	Inventor's Signature: <i>Bodo Asmussen</i>	Date 10.05.2000
	Residence: Im Schloßgarten 10 D-56170 Bendorf, Germany <i>DEX</i>	Citizenship: German	
	Post Office Address: Same as above.		
3	Full Name: Andreas Koch	Inventor's Signature: <i>Andreas Koch</i>	Date 10.05.2000
	Residence: Grubenstrasse 1 D-56581 Melsbach, Germany <i>DEX</i>	Citizenship: German	
	Post Office Address: Same as above.		
4	Full Name: Thomas Hille	Inventor's Signature: <i>Thomas Hille</i>	Date 10.05.2000
	Residence: Am Moogsberg 2A D-56567 Neuwied, Germany <i>DEX</i>	Citizenship: German	
	Post Office Address: Same as above.		

5	Full Name: Bernd Adam	Inventor's Signature: <i>Bernd Adam</i>	10.05.2000
	Residence: Marktplatz 11 D-34613 Treysa, Germany <i>DEX</i>	Citizenship: German	
	Post Office Address: Same as above.		
6	Full Name: Rudolf Matusch	Inventor's Signature: <i>Rudolf Matusch</i>	Date 10.05.2000
	Residence: Am Hasenkuppel 18A D-35041 Marburg, Germany <i>DEX</i>	Citizenship: German	
	Post Office Address: Same as above.		

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies were found during scanning:

☐ Page(s) 7-25 of Claims were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Scanned copy is best available.